MRI-based prostate SBRT boosts provide lower coverage of PSMA-PET-defined lesions
In 20 high-risk prostate cancer patients, MRI and PSMA-PET boost targets frequently disagreed, with significantly lower dose coverage of PET-defined lesions.
In 20 high-risk prostate cancer patients, MRI and PSMA-PET boost targets frequently disagreed, with significantly lower dose coverage of PET-defined lesions.
Five studies worth your time this week, spanning lung SBRT, brain metastases, thoracic reirradiation, AI contouring and prostate dose escalation.
In NRG/RTOG 0424, cognitive decline affected 50% at six months and 40% at one year, despite stable average quality-of-life scores.
All 13 CNS germinoma patients remained event-free at five years after upfront RT, but treatment-sequencing comparisons in nongerminomatous tumors remain inconclusive.
In synchrotron UHDR proton and carbon-ion beams, dose-averaged dose rate better described chamber recombination than conventional field-averaged metrics.
In 70 patients, a 7.5-Gy stereotactic tumor-bed boost before whole-breast RT produced 7% grade 2 fibrosis and no grade ≥3 late toxicity.
In a 23-patient phase I study, five-fraction partial-breast SBRT produced no in-breast recurrences, while favorable cosmesis declined to 73.7% at three years.
In 16 sinonasal cancer planning cases, LET optimization reduced chiasm LET from 3.1 to 2.3 keV/μm while maintaining target coverage.
In 51 patients with unresectable stage III NSCLC, an adaptive SBRT boost achieved 62.8% two-year locoregional control, with hemoptysis raising safety concerns.
CT-defined sarcopenia increased from 23% before pelvic RT to 42% at three months, while bedside bioimpedance missed many cases.
Across four proton plans, all 12 recalculations passed 3%/3 mm gamma, but stopping-power choices shifted distal range by up to 1.9 mm.
In 20 prostate patients with hip replacements, implant-trained synthetic CT models closely reproduced CT dose, but two cases with rectal air had outliers.
Among 36 MR-Linac consortium experts, 86% reported access to the technology, but only 28% treated head and neck cancer on the platform.
Across 149 cervical radiotherapy fractions, adding ultrasound to CBCT improved uterocervix visibility but increased correct plan selection by only one percentage point.
In TARGET, focal VMAT or HDR brachytherapy boosts achieved 98.5% three-year control within treated prostate lesions, while four recurrences arose outside the boost.